瑞博生物-B(06938)：核心产品VORTOSIRAN完成针对SPAF适应症的 2b期临床试验申请递交

14 4 月, 2026

One Min Read

11 Views

Last Update: 14 4 月, 2026

Written By

Other Articles

Previous

北海康成-B(01228)股东将股票存入摩根士丹利香港证券存仓市值2.55亿港元

Next

贝莱德转向超配股票! 高呼风险偏好回归紧抓半导体、能源独立与电力基建风向

Related Posts

先消灭低价股！

1 Min Read

假期市场思考：A股还是美股？

1 Min Read

香港证券两日成交额破百亿！港股仍有市场？

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept